Find verified Orforglipron API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Orforglipron for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Orforglipron API.
Alternate Names: GLP-1 receptor agonist 1, 1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-
CAS No: 2212020-52-3
PubChem CID: 137319706
Mol Formula: C48H48F2N10O5
Mol Weight: 883.0 g/mol
IUPAC Name: 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl -Show More
Drug Class: GLP‑1 Receptor Agonists
Commercial / Development Status: Commercial APIs
Source / Manufacturing Origin: Synthetic APIs
API Description: Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly for treating obesity and type 2 diabetes. It is taken once daily by mouth without food or water restrictions and has been shown to reduce blood sugar levels and body weight effectively, with a safety profile similar to other GLP-1 agonists
